Mount Sinai and Harbour BioMed collaborated to advance treatment of cancer and Coronavirus COVID-19
On Mar. 6, 2020, Mount Sinai Health System and Harbour BioMed (HBM) announced a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.
Tags:
Source: Icahn School of Medicine at Mount Sinai
Credit:
